Low-dose atorvastatin in severe chronic kidney disease patients: a randomized, controlled endpoint study.

@article{Stegmayr2005LowdoseAI,
  title={Low-dose atorvastatin in severe chronic kidney disease patients: a randomized, controlled endpoint study.},
  author={B. G. Stegmayr and Mats Br{\"a}nnstr{\"o}m and S Bucht and V Crougneau and Em{\"o}ke M Dim{\'e}ny and Anders Ekspong and Mats Eriksson and Barbara Granroth and K C Gr{\"o}ntoft and Henrik Hadimeri and Benny Holmberg and Bo Ingman and Bengt Isaksson and Gunnar Johansson and Kerstin Lindberger and L O Lundberg and Laila Mikaelsson and Eva A Olausson and Beata Persson and Hans Stenlund and Ann Marie Wikdahl},
  journal={Scandinavian journal of urology and nephrology},
  year={2005},
  volume={39 6},
  pages={489-97}
}
OBJECTIVE There have been no endpoint studies with statins for patients with severe renal failure. The purpose of this prospective, open, randomized, controlled study was to investigate whether atorvastatin (10 mg/day) would alter cardiovascular endpoints and the overall mortality rate of patients with chronic kidney disease stage 4 or 5 (creatinine clearance < 30 ml/min). MATERIAL AND METHODS The study subjects comprised 143 patients who were randomized either to placebo (controls; n=73… CONTINUE READING

Connections & Topics

Mentioned Connections BETA
Analysis focused on the primary endpoints of all - cause mortality , non - lethal acute myocardial infarction , coronary artery bypass graft surgery and percutaneous transluminal coronary angioplasty .
Analysis focused on the primary endpoints of all - cause mortality , non - lethal acute myocardial infarction , coronary artery bypass graft surgery and percutaneous transluminal coronary angioplasty .
Analysis focused on the primary endpoints of all - cause mortality , non - lethal acute myocardial infarction , coronary artery bypass graft surgery and percutaneous transluminal coronary angioplasty .
Analysis focused on the primary endpoints of all - cause mortality , non - lethal acute myocardial infarction , coronary artery bypass graft surgery and percutaneous transluminal coronary angioplasty .
Analysis focused on the primary endpoints of all - cause mortality , non - lethal acute myocardial infarction , coronary artery bypass graft surgery and percutaneous transluminal coronary angioplasty .
Analysis focused on the primary endpoints of all - cause mortality , non - lethal acute myocardial infarction , coronary artery bypass graft surgery and percutaneous transluminal coronary angioplasty .
Analysis focused on the primary endpoints of all - cause mortality , non - lethal acute myocardial infarction , coronary artery bypass graft surgery and percutaneous transluminal coronary angioplasty .
Analysis focused on the primary endpoints of all - cause mortality , non - lethal acute myocardial infarction , coronary artery bypass graft surgery and percutaneous transluminal coronary angioplasty .
Analysis focused on the primary endpoints of all - cause mortality , non - lethal acute myocardial infarction , coronary artery bypass graft surgery and percutaneous transluminal coronary angioplasty .
Analysis focused on the primary endpoints of all - cause mortality , non - lethal acute myocardial infarction , coronary artery bypass graft surgery and percutaneous transluminal coronary angioplasty .
The purpose of this prospective , open , randomized , controlled study was to investigate whether atorvastatin ( 10 mg / day ) would alter cardiovascular endpoints and the overall mortality rate of patients with chronic kidney disease stage 4 or 5 ( creatinine clearance < 30 ml / min ) .
The purpose of this prospective , open , randomized , controlled study was to investigate whether atorvastatin ( 10 mg / day ) would alter cardiovascular endpoints and the overall mortality rate of patients with chronic kidney disease stage 4 or 5 ( creatinine clearance < 30 ml / min ) .
The purpose of this prospective , open , randomized , controlled study was to investigate whether atorvastatin ( 10 mg / day ) would alter cardiovascular endpoints and the overall mortality rate of patients with chronic kidney disease stage 4 or 5 ( creatinine clearance < 30 ml / min ) .
The purpose of this prospective , open , randomized , controlled study was to investigate whether atorvastatin ( 10 mg / day ) would alter cardiovascular endpoints and the overall mortality rate of patients with chronic kidney disease stage 4 or 5 ( creatinine clearance < 30 ml / min ) .
The purpose of this prospective , open , randomized , controlled study was to investigate whether atorvastatin ( 10 mg / day ) would alter cardiovascular endpoints and the overall mortality rate of patients with chronic kidney disease stage 4 or 5 ( creatinine clearance < 30 ml / min ) .
The purpose of this prospective , open , randomized , controlled study was to investigate whether atorvastatin ( 10 mg / day ) would alter cardiovascular endpoints and the overall mortality rate of patients with chronic kidney disease stage 4 or 5 ( creatinine clearance < 30 ml / min ) .
The patients included were either non - dialysis ( n=33 ) , haemodialysis ( n=97 ) or peritoneal dialysis ( n=13 ) patients .
Analysis focused on the primary endpoints of all - cause mortality , non - lethal acute myocardial infarction , coronary artery bypass graft surgery and percutaneous transluminal coronary angioplasty .
Analysis focused on the primary endpoints of all - cause mortality , non - lethal acute myocardial infarction , coronary artery bypass graft surgery and percutaneous transluminal coronary angioplasty .
The patients included were either non - dialysis ( n=33 ) , haemodialysis ( n=97 ) or peritoneal dialysis ( n=13 ) patients .
The purpose of this prospective , open , randomized , controlled study was to investigate whether atorvastatin ( 10 mg / day ) would alter cardiovascular endpoints and the overall mortality rate of patients with chronic kidney disease stage 4 or 5 ( creatinine clearance < 30 ml / min ) .
The purpose of this prospective , open , randomized , controlled study was to investigate whether atorvastatin ( 10 mg / day ) would alter cardiovascular endpoints and the overall mortality rate of patients with chronic kidney disease stage 4 or 5 ( creatinine clearance < 30 ml / min ) .
All Topics